Effects of AMPK Activation on Insulin Sensitivity and Metabolism in Leptin-Deficient ob/ob Mice
- Robby Zachariah Tom*,1,
- Pablo M Garcia-Roves*,2,
- Rasmus J O Sjögren1,
- Lake Q Jiang1,
- Maria H Holmström1,
- Atul S Deshmukh1,
- Elaine Vieira1,
- Alexander V Chibalin1,
- Marie Björnholm1 and
- Juleen R Zierath1,2⇑
- 1Integrative Physiology, Department of Molecular Medicine and Surgery, Karolinska Institutet, SE-171 77 Stockholm, Sweden;
- 2Integrative Physiology, Department of Physiology and Pharmacology, Karolinska Institutet, SE-171 77 Stockholm, Sweden
- Corresponding Author: Juleen R. Zierath, E-mail:
AMP-activated protein kinase (AMPK) is a heterotrimeric complex, composed of a catalytic subunit (α) and two regulatory subunits (β and γ), which acts as a metabolic sensor to regulate glucose and lipid metabolism. A mutation in the γ3-subunit (AMPKγ3R225Q) increases basal AMPK phosphorylation, while concomitantly reducing sensitivity to AMP. AMPKγ3R225Q transgenic mice are protected against dietary-induced triglyceride accumulation and insulin resistance. We determined whether skeletal muscle-specific expression of AMPKγ3R225Q prevents metabolic abnormalities in leptin-deficient ob/ob mice (ob/ob-γ3R225Q). Glycogen content was increased, triglyceride content was decreased and diacylglycerol and ceramide content was unaltered in gastrocnemius muscle from ob/ob-γ3R225Q mice, whereas glucose tolerance was unaltered. Insulin-stimulated glucose uptake in extensor digitorum longus muscle during the euglycemic-hyperinsulinemic clamp was increased in lean γ3R225Q mice, but not in ob/ob-γ3R225Q mice. Acetyl-CoA carboxylase phosphorylation was increased in gastrocnemius muscle from γ3R225Q mutant mice independent of adiposity. Glycogen and triglyceride content was decreased after leptin treatment (5 days) in ob/ob mice, but not ob/ob-γ3R225Q mice. In conclusion, metabolic improvements arising from muscle-specific expression of AMPKγ3R225Q are insufficient to ameliorate insulin resistance and obesity in leptin-deficient mice. Central defects due to leptin deficiency may override any metabolic benefit conferred by peripheral overexpression of the AMPKγ3R225Q mutation.
* These authors contributed equally to the work.
- Received April 25, 2013.
- Accepted January 24, 2014.
- © 2014 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.